322 related articles for article (PubMed ID: 12476283)
1. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation.
Massenkeil G; Rackwitz S; Genvresse I; Rosen O; Dörken B; Arnold R
Bone Marrow Transplant; 2002 Dec; 30(12):899-903. PubMed ID: 12476283
[TBL] [Abstract][Full Text] [Related]
2. Basiliximab for the treatment of steroid-refractory acute graft-versus-host disease after unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation.
Wang JZ; Liu KY; Xu LP; Liu DH; Han W; Chen H; Chen YH; Zhang XH; Zhao T; Wang Y; Huang XJ
Transplant Proc; 2011 Jun; 43(5):1928-33. PubMed ID: 21693302
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease.
Schmidt-Hieber M; Fietz T; Knauf W; Uharek L; Hopfenmüller W; Thiel E; Blau IW
Br J Haematol; 2005 Aug; 130(4):568-74. PubMed ID: 16098072
[TBL] [Abstract][Full Text] [Related]
4. [Salvage treatment with infliximab of steroid-resistant graft-versus-host disease in allogeneic transplanted patients].
Motlló C; Ferrà C; López L; Morgades M; Batlle M; Ribera JM
Med Clin (Barc); 2011 Jun; 137(3):115-8. PubMed ID: 21543091
[TBL] [Abstract][Full Text] [Related]
5. Immunological effects in patients with steroid-refractory graft-versus-host disease following treatment with basiliximab, a CD25 monoclonal antibody.
Chakupurakal G; García-Márquez MA; Shimabukuro-Vornhagen A; Theurich S; Holtick U; Hallek M; Scheid C; von Bergwelt-Baildon M
Eur J Haematol; 2016 Aug; 97(2):121-7. PubMed ID: 26492560
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic effects of interleukin-2 receptor antagonists against graft-versus-host disease following unrelated donor peripheral blood stem cell transplantation.
Fang J; Hu C; Hong M; Wu Q; You Y; Zhong Z; Li W; Zou P; Hu Y; Xia L
Biol Blood Marrow Transplant; 2012 May; 18(5):754-62. PubMed ID: 21963619
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
[TBL] [Abstract][Full Text] [Related]
8. Matched and mismatched allogeneic stem-cell transplantation from unrelated donors using combined graft-versus-host disease prophylaxis including rabbit anti-T lymphocyte globulin.
Finke J; Schmoor C; Lang H; Potthoff K; Bertz H
J Clin Oncol; 2003 Feb; 21(3):506-13. PubMed ID: 12560442
[TBL] [Abstract][Full Text] [Related]
9. Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin.
McCaul KG; Nevill TJ; Barnett MJ; Toze CL; Currie CJ; Sutherland HJ; Conneally EA; Shepherd JD; Nantel SH; Hogge DE; Klingemann HG
J Hematother Stem Cell Res; 2000 Jun; 9(3):367-74. PubMed ID: 10894358
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation.
Ikegame K; Yoshihara S; Taniguchi Y; Kaida K; Inoue T; Okada M; Taniguchi K; Hasei H; Tamaki H; Fujioka T; Kato R; Soma T; Ogawa H
Exp Hematol; 2011 Aug; 39(8):880-90. PubMed ID: 21689724
[TBL] [Abstract][Full Text] [Related]
11. A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia.
Yahng SA; Kim JH; Jeon YW; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Kim HJ
Biol Blood Marrow Transplant; 2015 Jan; 21(1):119-29. PubMed ID: 25300871
[TBL] [Abstract][Full Text] [Related]
12. Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
Solomon SR; Sanacore M; Zhang X; Brown S; Holland K; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1828-34. PubMed ID: 25064745
[TBL] [Abstract][Full Text] [Related]
13. Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies.
Hebart H; Ehninger G; Schmidt H; Berner B; Reuss-Borst M; Waller HD; Müller CA; Einsele H
Bone Marrow Transplant; 1995 Jun; 15(6):891-4. PubMed ID: 7581087
[TBL] [Abstract][Full Text] [Related]
14. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of Basiliximab for the Prevention of Graft-versus-Host Disease in Patients Undergoing Hematopoietic Cell Transplantation with Minimal-Intensity Cyclophosphamide and Fludarabine.
Podichetty JT; Brinda BJ; Nelson RP; Karr AH; Prasad NK; Quinney S; Foxworthy Scott S; Kiel PJ
Pharmacotherapy; 2020 Jan; 40(1):26-32. PubMed ID: 31742732
[TBL] [Abstract][Full Text] [Related]
16. Prospective trial of high-dose chemotherapy followed by infusions of peripheral blood stem cells and dose-escalated donor lymphocytes for relapsed leukemia after allogeneic stem cell transplantation.
Takami A; Okumura H; Yamazaki H; Kami M; Kim SW; Asakura H; Endo T; Nishio M; Minauchi K; Kumano K; Sugimori N; Mori S; Takemoto Y; Shimadoi S; Ozaki J; Takaue Y; Nakao S
Int J Hematol; 2005 Dec; 82(5):449-55. PubMed ID: 16533751
[TBL] [Abstract][Full Text] [Related]
17. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant.
Kim JG; Sohn SK; Kim DH; Lee NY; Suh JS; Lee KS; Lee KB
Eur J Haematol; 2004 Jul; 73(1):56-61. PubMed ID: 15182339
[TBL] [Abstract][Full Text] [Related]
18. Daclizumab for children with corticosteroid refractory graft-versus-host disease.
Teachey DT; Bickert B; Bunin N
Bone Marrow Transplant; 2006 Jan; 37(1):95-9. PubMed ID: 16247417
[TBL] [Abstract][Full Text] [Related]
19. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
20. [Chimeric anti-CD25 monoclonal antibody for treating acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation].
Wang JZ; Liu KY; Xu LP; Liu DH; Chen YH; Huang XJ
Zhonghua Nei Ke Za Zhi; 2008 Nov; 47(11):923-5. PubMed ID: 19080235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
